This study sought to test whether aortic valve calcium (AVC) is independently associated with coronary and cardiovascular events in a primary-prevention population.
C alcific aortic valve disease is common in older adults, with an estimated prevalence of 25% in individuals older than 65 years of age (1) . Thought previously to be a degenerative disorder, the disease is now recognized to be an actively regulated biological process sharing many epidemiological (1) (2) (3) (4) and histopathological (5) similarities to coronary atherosclerosis.
In older adults without known cardiovascular disease, aortic sclerosis (the presence of valve calcium without hemodynamic obstruction) is associated with a 50% increase in risk of cardiovascular events (6) . Hypothesized mechanisms underlying this association include inflammation, subclinical atherosclerosis, and other shared biological mechanisms.
To determine whether the presence of aortic valve calcium (AVC), detected on computed tomography (CT) scans, predicts cardiovascular events in a younger cohort and to identify mechanisms underlying this association, we performed a prospective analysis in MESA (Multi-Ethnic Study of Atherosclerosis).
M E T H O D S
Study population: MESA is a National Heart, Lung, and Blood Institutesponsored, population-based investigation of subclinical cardiovascular disease and its progression (7) . In this study, a total of 6,814 individuals, ages 45 to 84 years, were recruited from 6 U.S. communities (Baltimore City and County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; New York, New York; and St. Paul, Minnesota) between July 2000 and August 2002. Pre-specified recruitment plans targeted 4 ethnic groups (white, black, Hispanic, and Chinese). Participants were excluded if they had physician-diagnosed cardiovascular disease before enrollment, including angina, myocardial infarction (MI), heart failure, stroke or transient ischemic attack, resuscitated cardiac arrest, or a cardiovascular intervention (e.g., coronary artery bypass graft, angioplasty, valve replacement, pacemaker/defibrillator placement). Subjects with subclinical aortic valve disease (e.g., bicuspid valves) were thus eligible for participation. The institutional review board at each participating institution approved MESA, and each participant provided informed written consent before enrollment. Demographic and covariate data. The comprehensive baseline MESA examination included a clinic visit, serum analyses, and a CT scan of the chest and heart. Information regarding the participants' demographic data and medical history, including medication use, was obtained by questionnaire. Ethnicity was self-reported. Baseline testing for and definitions of cardiovascular risk factors were described previously (8) . Serum samples were obtained after a 12-h fast and analyzed in a central laboratory (University of Vermont, Burlington, Vermont). C-reactive protein (CRP) concentrations were analyzed using the BNII high-sensitivity nephelometer (Dade Behring, Inc., Deerfield, Illinois). Diabetes and impaired fasting glucose were defined according to the 2003 American Diabetes Association fasting criteria algorithm or a history of diabetes treatment. Renal function was estimated using the Modification of Diet in Renal Disease equation. CT analysis. All MESA participants underwent baseline CT scans that were analyzed for both coronary artery calcium (CAC) and AVC. Three institutions used an electron beam tomography Imatron C150 scanner (GE Medical Systems, Milwaukee, Wisconsin), whereas 3 institutions used 4-slice multidetector CT scanners. Spatial resolution was 1.38 mm 3 for electron beam tomography (0.68 ϫ 0.68 ϫ 3.00 mm) and 1.15 mm 3 for multidetector CT (0.68 ϫ 0.68 ϫ 2.50 mm). Full details concerning the equipment, scanning methods, and quality control, including image calibration, phantom adjustment, and interscanner reproducibility, were reported previously (9,10).
All scans were sent to a central MESA CT reading center (Harbor-UCLA Research and Education Institute, Los Angeles, California). Calcium strongly attenuates x-rays, appears bright on CT scans, and is readily differentiated from surrounding tissue. The methods for CAC scoring in MESA were described previously (11) . Consistent with accepted methodology (10, (12) (13) (14) , lesions were classified as AVC if they resided within the aortic valve leaflets, exclusive of the aortic annulus or coronary arteries, and contained Ն3 contiguous pixels of Ն130 Hounsfield units of brightness. Using Agatston methodology (15), single-lesion calcium contents were summed to give a total AVC score. If no lesions reached threshold, the AVC score was 0. Outcomes assessment. MESA participants were followed prospectively from the time of enrollment. To capture unreported events, telephone interviews were conducted every 9 to 12 months. More than 99% of self-reported hospitalizations and 97% of cardiovascular outpatient diagnoses and procedures were investigated through medical record review, and incident aortic valve disease and valve replace- ments were identified by ICD-9 diagnosis and procedure codes. Death investigations included examination of death certificates and next-of-kin interviews. Each event was adjudicated by 2 physicians, with committee review of disagreements. Deaths potentially due to cardiovascular causes were adjudicated by the full committee.
The combined endpoints of major coronary events (MI, resuscitated cardiac arrest, and cardiovascular death) and major cardiovascular events (coronary events plus nonfatal or fatal stroke) were pre-specified by MESA. Definite or probable MIs were defined by symptoms, electrocardiographic findings, and abnormal cardiac biomarker levels (Ͼ2 times upper limits of normal). Strokes were defined as neurological deficits lasting Ͼ24 h or lesions on brain imaging consistent with a localized ischemic or hemorrhagic event. Data analyses. MESA participants were categorized according to the presence (AVC score Ͼ0) or absence (AVC score ϭ 0) of AVC on baseline examination. Differences in baseline demographic features were compared using chi-square test of proportions or the Student t test comparison of means where appropriate. Event rates were described and displayed using Kaplan-Meier cumulative events methods. The risks associated with the presence of AVC, adjusted for baseline demographic features, were estimated using Cox proportional hazards regression. Schoenfeld residual and log-minus-log survival plots were used to confirm the proportional hazards assumptions of these models. Incremental model building was performed to demonstrate the impact of baseline factors on overall risk. Model 1 included adjustments for age, sex, and race. Model 2 additionally adjusted for body size, cardiovascular risk factors, and renal function. Model 3 additionally included adjustment for CRP, which was log-transformed before inclusion due to its skewed distribution. Exploratory models adding fibrinogen and interleukin-6 were also performed, but did not substantively alter the results.
Model 4 included adjustment for baseline CAC score, modeled as a log-transformed variable using the sum of the CAC score plus 1 (i.e., log[CAC ϩ 1]) to permit inclusion of subjects with CAC scores of 0. Exploratory analyses using alternative CAC transformations were performed, including Greenland categories (0, 1 to 100, 100 to 300, and Ͼ300) (16) and a square root transformation, but these did not substantively alter the analytical results.
All statistical analyses were performed with Stata version 11.0 for Windows (StataCorp, College Station, Texas). Statistical significance was defined as p Ͻ 0.05, and hazard ratios (HRs) are reported with 95% confidence intervals (CIs).
R E S U L T S
Study subjects. Of the 6,814 participants initially recruited into MESA, 6,685 were included in these analyses. Participants were excluded because of cardiovascular events before enrollment (n ϭ 5, 0.1%), lost to follow-up (n ϭ 33, 0.5%), no baseline AVC scoring (n ϭ 1, 0.01%), and missing covariate data (n ϭ 90, 1.3%). Two excluded subjects had strokes during follow-up, 1 each with and without AVC at baseline.
The baseline characteristics of the study cohort are shown in Table 1 . AVC was observed in 13% of the cohort at baseline, with a median Agatston score of 58 (interquartile range: 20 to 149). Subjects with AVC were older and more likely to be male and had worse overall cardiovascular risk factor profiles. Additionally, subjects with AVC were more likely to have CAC and to have higher CAC scores (Fig. 1) .
Subjects were followed for a median of 5.8 years (interquartile range: 5.6 to 5.9 years), with a maximum follow-up of 7.1 years. During this period, there were 40 cases of incident aortic valve disease and 22 aortic valve replacements, as well as 160 coronary and 255 cardiovascular events. Risk of coronary and cardiovascular events. Figure 2 depicts the unadjusted Kaplan-Meier cumulative event curves for major coronary and cardiovascular events, respectively. After adjusting for age, race, and sex (Table 2 , model 1), the presence of AVC was a strong predictor of both cardiovascular and coronary events. Although these risks were attenuated after adjusting for known atherosclerotic risk factors (Table 2 The prevalence of coronary artery calcium (CAC) categories (CAC score ϭ 0, Ͻ100, 100 to 300, and Ͼ300) among MESA participants with (n ϭ 894) and without (n ϭ 5,791) aortic valve calcium (AVC) at baseline. Participants with baseline AVC had a higher prevalence of CAC (87.1% vs. 45.1%, p Ͻ 0.0001) compared with those without AVC, with skewing of the distribution of CAC scores toward more severe calcification.
CI: 1.37 to 5.40; p ϭ 0.004) when subjects with clinical progression (incident clinical valve disease or valve replacement, n ϭ 54) or higher baseline calcium (AVC score Ͼ100, n ϭ 293) were excluded. Increasing tertiles of AVC were observed to have increased event rates (Fig. 3) . Compared with those without AVC, those with AVC scores of 1.9 to 29.2, 29.4 to 107, and 107.5 to 7,672 had a 2.18-fold (95% CI: 0.93 to 5.12), 3.10-fold (95% CI: 1.31 to 7.37), and 3.02-fold (95% CI: 1.22 to 7.43) higher risk of cardiovascular death, respectively, after full adjustment. Risk by race/ethnicity. After adjustment for demographics, cardiovascular risk factors, inflammation, and CAC score, there were no significant differences by race/ethnicity in the association of AVC with either cardiovascular (p interaction ϭ 0.12) or coronary (p interaction ϭ 0.13) events.
D I S C U S S I O N
Calcific aortic valve disease begins in midlife as a clinically latent but progressive disorder and often is detected incidentally. Yet even in this latent, preobstructive phase, the presence of aortic valve calcium appears to be a marker of increased cardiovascular risk. Previous results from the CHS (Cardiovascular Health Study) showed that, among adults older than 65 years of age, echocardiographically detected aortic sclerosis was associated with a 50% increased risk of cardiovascular mortality (6) . In that study, aortic sclerosis also was associated with a 42% increase in risk of MI. However, these analyses were unable to control for the presence of subclinical atherosclerosis and systemic inflammation, plausible mediators of these associations.
Our results extend these previous findings to a younger, healthier, and multiethnic population and offer a partial explanation for the observed association between aortic sclerosis and coronary events. Among participants age 45 to 84 years and free of cardiovascular disease at baseline and after adjustment for demographics and cardiovascular risk profiles, the presence of AVC on CT was associated with a significant, 50% higher risk of cardiovascular events and a 72% higher risk of coronary events. Notably, these results are similar in magnitude to echocardiographically detected aortic sclerosis in CHS. These risk estimates were unaltered by adjustment for inflammatory biomarkers, suggesting that systemic inflammation did not account for these associations.
Conversely, the risk estimates were attenuated substantially after adjusting for the severity of subclinical atherosclerosis, as estimated by CAC scores. CAC has been strongly and independently associated with cardiovascular events across a range of age, ethnic, and 
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Unadjusted Kaplan-Meier cumulative event curves depicting the cardiovascular (A) and coronary (B) events rates among participants with (red) and without (green) aortic valve calcium (AVC) at baseline. At the median 5.8 years of follow-up, participants with AVC had higher unadjusted rates of both cardiovascular (3.2% vs. 10.2%, p Ͻ 0.0001) and coronary (1.9% vs. 6.9%, p Ͻ 0.0001) events compared with participants without AVC. risk profiles (8,16 -18) . We found a strong association between the presence of AVC and both the prevalence and severity of CAC in MESA (Fig. 1 In pre-specified exploratory analyses, AVC remained an independent predictor of cardiovascular mortality after adjustment for risk factors and CAC severity. Given the low event rate, this finding must be interpreted with caution. Nonetheless, this finding is intriguing because this excess mortality may be unrelated to progressive valve disease. Participants with substantial calcium progression likely would have developed symptoms and undergone valve replacement, whereas death from asymptomatic aortic stenosis is relatively uncommon (19) , even in very severe aortic stenosis (20) . Previous studies suggest that aortic stenosis is uncommon with AVC scores Ͻ150 (13, 14) , and exclusion of those with known progression and those with AVC scores Ͼ100 did not alter the risk association. The mechanisms underlying this observed association remain unexplained, and further investigations are warranted. Study limitations. First, AVC was not a prespecified variable in MESA, and CT scans obtained for the purpose of CAC scoring were analyzed retrospectively. Second, only baseline risk factor profiles were included as covariates, and changes in profiles were not evaluated. Third, the rate of cardiovascular events in MESA was low, reducing No AVC  5791  5753  5668  5580  5480  5338  923   Tertile 1  298  297  287  277  272  264  48   Tertile 2  297  295  288  284  275  256  40   Tertile 3  299  290  278  268  258  242 Unadjusted Kaplan-Meier cumulative event curves for the combined endpoint of cardiovascular (CV) death or resuscitated cardiac arrest (RCA), stratified by tertiles of baseline aortic valve calcium (AVC) score. At the median 5.8 years of follow-up, the unadjusted event rate for participants without baseline AVC was 0.5% compared with event rates of 2.1% (tertile 1), 3.2% (tertile 2), and 3.7% (tertile 3) for those with increasing severity of baseline AVC. After full adjustment for age, sex, cardiovascular risk factors, renal function, and coronary artery calcium scores, there remained a 1.48-fold (95% confidence interval: 1.14 to 1.95; p ϭ 0.004) increase in risk of CV death or RCA per-tertile increase in AVC score. Tables 1 and 2 .
the power to detect risk associations. Finally, participants and their physicians were informed of high CAC scores, knowledge that may have prompted therapy to reduce cardiovascular risk; however, such treatment would likely bias results toward the null.
C O N C L U S I O N S
In a multiethnic cohort without clinical cardiovascular disease at baseline, AVC was associated with risks of coronary and cardiovascular events beyond those predicted by traditional risk factors. These risk associations were attenuated after adjustment for CAC but not for inflammatory markers, suggesting that AVC partly serves as a marker of subclinical atherosclerosis severity. Whether AVC adds to cardiovascular risk prediction beyond Framingham risk categorization merits additional investigation. Finally, through mechanisms yet to be elucidated, the association of AVC with excess cardiovascular mortality remained, even after adjustment for risk factors, inflammation, and subclinical atherosclerosis.
